NCT00144963已完成1 期
Phase I-II Study of Liposomal Vincristine (VSLI) and Dexamethasone in Relapsed or Refractory Acute Lymphoblastic Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 36
- 试验地点
- 3
- 主要终点
- MTD of VSLI
研究概览
简要总结
The purpose of this study is to find the highest safe dose and to assess the anti-tumor effect of liposomal vincristine with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
详细描述
OBJECTIVES:
- Determine the maximum tolerated dose (MTD) of liposomal vincristine given with dexamethasone in patients with relapsed or refractory acute lymphoblastic leukemia (ALL).
- Determine the efficacy of liposomal vincristine given with dexamethasone in these patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previously treated, relapsed or refractory ALL (including lymphoblastic lymphoma and Burkitt's subtypes) with measurable disease.
- •Performance status ≤3 (ECOG).
- •All ages are eligible. Those aged 12 years or older may be counted towards the MTD in the Phase I portion of the trial. Pediatric patients are eligible, but must be treated at a dose level previously tested in an adult (one full course).
- •Adequate liver function (bilirubin ≤2 x upper limit normal), and renal function (creatinine ≤2 x upper limit normal).
- •Negative pregnancy test in females of childbearing potential.
- •Patients with prior history of stem cell transplant are eligible if they meet all other eligibility requirements.
排除标准
- •Active serious infection not controlled by oral or intravenous antibiotics.
- •Treatment with any investigational agents or chemotherapy agents in the last 21 days before study entry, unless full recovery from side effects has occurred or the patient has rapidly progressive disease judged to be life threatening by the Investigator.
- •Concurrent treatment with other anti-cancer agents other than dexamethasone.
- •Known CNS leukemia or lymphoma requiring intrathecal or craniospinal radiation therapy or with CNS neuropathy limiting evaluation of study drug. Patients with controlled CNS disease (no progression signs or symptoms at the time of study entry) may be eligible after approval by the Principal Investigator. Lumbar puncture not required in asymptomatic patients.
- •Prior history of Grade 3 or 4 sensory or motor neuropathy related to chemotherapeutic treatment, or persistent Grade 2 or greater active neuropathy.
- •History of active neurologic disorders unrelated to chemotherapy (including familial neurologic diseases and acquired demyelinating disorders).
- •Prior history of hypersensitivity reactions to vincristine or any of the other components of VSLI.
- •Pregnant and/or lactating women; or fertile men or women not willing to use contraception.
研究组 & 干预措施
VSLI
Experimental
Vincristine Sulfate Liposomes Injection (VSLI)
干预措施: Vincristine Sulfate Liposomes Injection (Drug)
VSLI
Experimental
Vincristine Sulfate Liposomes Injection (VSLI)
干预措施: Dexamethasone (Drug)
结局指标
主要结局
MTD of VSLI
时间窗: 6 weeks
Subjects had to receive at least 1 course consisting of 4 weekly infusions of VSLI at the assigned drug dose with a minimum 2 weeks of observation after the last VSLI dose to be included in the evaluation of the MTD.
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
2 期
Liposomal Vincristine for Pediatric and Adolescent Patients With Relapsed MalignanciesSoft Tissue SarcomaOsteosarcomaLymphomaLeukemiaWilms' TumorNCT00038207M.D. Anderson Cancer Center29
已完成
1 期
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic DysfunctionMalignant MelanomaNCT00145041Acrotech Biopharma Inc.7
Unknown
3 期
Phase III Study of Vincristine Sulfate Liposome For Injection In Adults With Naïve Acute Lymphoblastic LeukemiaAdult Acute Lymphoblastic LeukemiaNCT02072785Nanjing Luye Sike Pharmaceutical Co., Ltd.480
已完成
1 期
Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's DiseaseTumorsHodgkins DiseaseNon-Hodgkins LymphomaNCT00364676Spectrum Pharmaceuticals, Inc67
Unknown
1 期
Dose Escalation Study of Liposomal Paclitaxel With/Without Capecitabine in Patients With Advanced Gastric CarcinomaGastric CarcinomaNCT00639522Nanjing Sike Pharmaceutical Co., Ltd.18